Delivering amoxicillin at the infection site – a rational design through lipid nanoparticles

References

• Meyler’s Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions15th edAmsterdamElsevier2006
   Google Scholar
• MalfertheinerPMegraudFO’MorainCAEuropean Helicobacter Study GroupManagement of Helicobacter pylori infection – the Maastricht IV/Florence consensus reportGut201261564666422491499
   PubMed Web of Science ®Google Scholar
• BoyanovaLMitovIVladimirovBHelicobacter pyloriNorfolkCaister Academic Press2011
   Google Scholar
• MishraSIs Helicobacter pylori good or bad?Eur J Clin Microbiol Infect Dis201332330130423132690
   PubMedGoogle Scholar
• TsujiANakashimaEHamanoSYamanaTPhysicochemical properties of amphoteric beta-lactam antibiotics I: stability, solubility, and dissolution behavior of amino penicillins as a function of pHJ Pharm Sci19786781059106627624
   PubMed Web of Science ®Google Scholar
• NägeleEMoritzRStructure elucidation of degradation products of the antibiotic amoxicillin with ion trap MS(n) and accurate mass determination by ESI TOFJ Am Soc Mass Spectrom200516101670167616099170
   PubMedGoogle Scholar
• Barzegar-JalaliMAdibkiaKValizadehHKinetic analysis of drug release from nanoparticlesJ Pharm Pharm Sci200811116717718471378
   PubMed Web of Science ®Google Scholar
• LopesDNunesCMartinsMCSarmentoBReisSEradication of Helicobacter pylori: Past, present and futureJ Control Release201418916918624969353
   PubMed Web of Science ®Google Scholar
• LopesDNunesCFontainePSarmentoBReisSProof of pore formation and biophysical perturbations through a 2D amoxicillin-lipid membrane interaction approachBiochim Biophys Acta Biomembr20171859580381228159461
   PubMedGoogle Scholar
• MobleyHLTMendzGLHazellSLHelicobacter pylori: Physiology and GeneticsWashington (DC)ASM Press2001
   Google Scholar
• HuhAJKwonYJ“Nanoantibiotics”: a new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistanteraJ Control Release2011156212814521763369
   PubMed Web of Science ®Google Scholar
• FalloneCAChibaNvan ZantenSVThe Toronto Consensus for the Treatment of Helicobacter pylori Infection in AdultsGastroenterology201615115169.e1427102658
   PubMed Web of Science ®Google Scholar
• CaiJHuangHSongWPreparation and evaluation of lipid polymer nanoparticles for eradicating H. pylori biofilm and impairing antibacterial resistance in vitroInt J Pharm2015495272873726417849
   PubMedGoogle Scholar
• JingZWJiaYYWanNDesign and evaluation of novel pH-sensitive ureido-conjugated chitosan/TPP nanoparticles targeted to Helicobacter pyloriBiomaterials20168427628526851392
   PubMed Web of Science ®Google Scholar
• ArifMDongQJRajaMAZeenatSChiZLiuCGDevelopment of novel pH-sensitive thiolated chitosan/PMLA nanoparticles for amoxicil-lin delivery to treat Helicobacter pyloriMater Sci Eng C Mater Biol Appl201883172429208276
   PubMed Web of Science ®Google Scholar
• AwasthiRKulkarniGTDevelopment and characterization of amoxicillin loaded floating microballoons for the treatment of Helicobacter pylori induced gastric ulcerAsian J Pharm Sci201383174180
   Google Scholar
• DeySKDePKDeAFloating mucoadhesive alginate beads of amoxicillin trihydrate: A facile approach for H. pylori eradicationInt J Biol Macromol20168962263127177460
   PubMed Web of Science ®Google Scholar
• SinghDYPrasadNKDouble liposomes mediated dual drug targeting for treatment of Helicobacter pylori infectionsPharmazie201166536837321699071
   PubMed Web of Science ®Google Scholar
• BattagliaLGallarateMLipid nanoparticles: state of the art, new preparation methods and challenges in drug deliveryExpert Opin Drug Deliv20129549750822439808
   PubMed Web of Science ®Google Scholar
• SeverinoPAndreaniTMacedoASCurrent state-of-art and new trends on lipid nanoparticles (SLN and NLC) for oral drug deliveryJ Drug Deliv2012201220110
   Google Scholar
• RuizCFalcocchioSPastorFIJSasoLDiazPHelicobacter pylori EstV: identification, cloning, and characterization of the first lipase isolated from an epsilon-proteobacteriumAppl Environ Microbiol20077382423243117293528
   PubMedGoogle Scholar
• MendzGLLimTNHazellSLFluorinated probes to measure carboxylesterase activities using 19F NMR spectroscopy: application to erythrocytes and Helicobacter pyloriArch Biochem Biophys199330522522608373162
   PubMedGoogle Scholar
• SeabraCLNunesCGomez-LazaroMDocosahexaenoic acid loaded lipid nanoparticles with bactericidal activity against Helicobacter pyloriInt J Pharm20175191–212813728088639
   PubMed Web of Science ®Google Scholar
• PelgriftRYFriedmanAJNanotechnology as a therapeutic tool to combat microbial resistanceAdv Drug Deliv Rev20136513–141803181523892192
   PubMed Web of Science ®Google Scholar
• LopesDNunesCMartinsMCLSarmentoBReisSTargeting strategies for the treatment of Helicobacter pylori infectionsNaikJNano based drug delivery Zagreb Nano Based Drug Delivery ZagrebCroatiaIAPC Publishing2015339366
   Google Scholar
• FiguraNMarcolongoRCavalloGPolysorbate 80 and Helicobacter pylori: a microbiological and ultrastructural studyBMC Microbiol201212121722998649
   PubMedGoogle Scholar
• JackmanJAYoonBKLiDChoNJNanotechnology formulations for antibacterial free fatty acids and monoglyceridesMolecules201621330526950108
   PubMed Web of Science ®Google Scholar
• SunCQO’ConnorCJRobertonAMAntibacterial actions of fatty acids and monoglycerides against Helicobacter pyloriFEMS Immunol Med Microbiol2003361–291712727360
   PubMed Web of Science ®Google Scholar
• JungSWThamphiwatanaSZhangLObonyoMMechanism of antibacterial activity of liposomal linolenic acid against Helicobacter pyloriPLoS One2015103e011651925793403
   PubMed Web of Science ®Google Scholar
• ObonyoMZhangLThamphiwatanaSPornpattananangkulDFuVZhangLAntibacterial activities of liposomal linolenic acids against antibiotic-resistant Helicobacter pyloriMol Pharm2012992677268522827534
   PubMedGoogle Scholar
• LingwoodCAHuescaMKuksisALingwoodCAThe glycerolipid receptor for Helicobacter pylori (and exoenzyme S) is phosphatidyl-ethanolamineInfect Immun1992606247024741587616
   PubMed Web of Science ®Google Scholar
• SinghBKapilRNandiMAhujaNDeveloping oral drug delivery systems using formulation by design: Vital precepts, retrospect and prospectsExpert Opin Drug Deliv20118101341136021790511
   PubMed Web of Science ®Google Scholar
• HassaniSPellequerYLamprechtASelective adhesion of nanoparticles to inflamed tissue in gastric ulcersPharm Res20092651149115419205850
   PubMed Web of Science ®Google Scholar
• AllenAFlemströmGGastroduodenal mucus bicarbonate barrier: protection against acid and pepsinAm J Physiol Cell Physiol20052881C1C1915591243
   PubMed Web of Science ®Google Scholar
• International Standard ISO 10993-5Biological Evaluation of Medical Devices–Part 5: Tests for in vitro CytotoxicityGeneva, Switzerland2009
   Google Scholar
• García-GonzálezLYépez-MulíaLGanemAEffect of β-cyclodextrin on the internalization of nanoparticles into intestine epithelial cellsEur J Pharm Sci20168111311826478186
   PubMedGoogle Scholar
• PolakovicMGörnerTGrefRDellacherieELidocaine loaded biodegradable nanospheres. II. Modelling of drug releaseJ Control Release1999602–316917710425323
   PubMedGoogle Scholar
• HonarySZahirFEffect of zeta potential on the properties of nano-drug delivery systems-a review (Part 1)Trop J Pharm Res2013122255264
   Web of Science ®Google Scholar
• SinghRLillardJWJrNanoparticle-based targeted drug deliveryExp Mol Pathol200986321522319186176
   PubMed Web of Science ®Google Scholar
• das NevesJSarmentoBPrecise engineering of dapivirine-loaded nanoparticles for the development of anti-HIV vaginal microbicidesActa Biomater201518778725700657
   PubMed Web of Science ®Google Scholar
• IqbalMZafarNFessiHElaissariADouble emulsion solvent evaporation techniques used for drug encapsulationInt J Pharm2015496217319026522982
   PubMed Web of Science ®Google Scholar
• PaysKGiermanska-KahnJPoulignyBBibetteJLeal-CalderonFDouble emulsions: how does release occur?J Control Release2002791–319320511853931
   PubMedGoogle Scholar
• GoddardAFJessaMJBarrettDAEffect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juiceGastroenterology199611123583678690200
   PubMed Web of Science ®Google Scholar
• ZhangX-YNgTKBreleńMEContinuous exposure to nonlethal doses of sodium iodate induces retinal pigment epithelial cell dysfunctionSci Rep20166111328442746
   PubMed Web of Science ®Google Scholar
• HesseySJSpencerJWyattJIBacterial adhesion and disease activity in Helicobacter associated chronic gastritisGut19903121341382311970
   PubMedGoogle Scholar
• YangJCLuCWLinCJTreatment of Helicobacter pylori infection: current status and future conceptsWorld J Gastroenterol201420185283529324833858
   PubMed Web of Science ®Google Scholar
• FeldötöZPetterssonTDėdinaitėAMucin-electrolyte interactions at the solid-liquid interface probed by QCM-DLangmuir20082473348335718266398
   PubMedGoogle Scholar
• GriffithsPCOcchipintiPMorrisCHeenanRKKingSMGumbletonMPGSE-NMR and SANS studies of the interaction of model polymer therapeutics with mucinBiomacromolecules201011112012519950890
   PubMed Web of Science ®Google Scholar
• Bravo-OsunaINoirayMBriandEInterfacial interaction between transmembrane ocular mucins and adhesive polymers and dendrimers analyzed by surface plasmon resonancePharm Res20122982329234022565639
   PubMedGoogle Scholar
• CaicedoJAPerillaJEEffect of pH on the rheological response of recongastric mucinIngeniería e Investigación20153524348
   Google Scholar
• LeeSMüllerMRezwanKSpencerNDPorcine gastric mucin (PGM) at the water/poly(dimethylsiloxane) (PDMS) interface: influence of pH and ionic strength on its conformation, adsorption, and aqueous lubrication propertiesLangmuir200521188344835316114941
   PubMed Web of Science ®Google Scholar
• CaoXBansilRBhaskarKRpH-dependent conformational change of gastric mucin leads to sol-gel transitionBiophys J19997631250125810049309
   PubMedGoogle Scholar
• CelliJPTurnerBSAfdhalNHHelicobacter pylori moves through mucus by reducing mucin viscoelasticityProc Natl Acad Sci200910634143211432619706518
   PubMed Web of Science ®Google Scholar